PLaybook
HOW WE DO IT
Our selection process is at the core of identifying promising assets for development. We leverage an extensive network of ambassadors, who are positioned in key universities across Brazil, to scout and recommend scientific research with high investment potential. These researchers work on projects validated by initial laboratory studies, allowing us to select assets that are already demonstrating promise.
We focus on scientific projects that address significant medical needs and that are ready for pre-clinical development. Our unique approach ensures that we identify assets early, offering us the opportunity to invest in their development and bring them to a stage of readiness for acquisition by major pharmaceutical companies.
MKM Biotech operates with a "build-to-buy" investment model, which focuses on investing in research that can bridge the gap between scientific discovery and acquisition by the pharmaceutical industry. We invest in projects at the pre-clinical stage, providing the necessary financial and intelectual support to advance research across the pre-clinical studies until the IND patent.
By concentrating on pre-clinical development, we reduce the high costs typically associated with later clinical trials. Our approach allows us to maximize returns by positioning the assets for acquisition while they still offer substantial upside potential, with valuations expected to increase significantly after Phase 1 trials.
At MKM Biotech, internationalization is a key pillar of our strategy to maximize the potential of our assets. We aim to position our drug candidates for global markets from the early stages of development, ensuring that all research, intellectual property, and regulatory processes align with international standards. By registering patents in the United States and other major pharmaceutical markets, we significantly increase the attractiveness of our assets to global pharmaceutical companies.
Our focus on internationalization allows us to tap into the largest and most lucrative pharmaceutical markets. By aligning our assets with global market demands, we can drive higher valuations and increase the chances of successful exits, all while ensuring that our innovations reach patients around the world.
Our research development strategy is carefully designed to advance scientific discoveries efficiently. We hire the most recognized international Certified Research Organizations (CROs) to ensure the quality and reliability of the studies, particularly during animal testing. To optimize costs, we conduct smaller-scale tests locally in Brazil, only engaging with CROs for crucial tests once results are certain.
By taking an active role in managing the research process, MKM Biotech accelerates the development timeline while maintaining a high standard of scientific rigor. This approach ensures that our assets are well-positioned for international recognition and prepared for eventual M&A, with significant reductions in risk for potential buyers.
M&A is the primary exit strategy for our investments, typically occurring at the end of pre-clinical testing or the start of Phase 1 clinical trials. We negotiate the value of the asset based on its projected market potential and milestones achieved. As the asset progresses through regulatory approvals, its valuation increases and, more often than not, these deals have additional payments as those milestones are reached.
In addition to the upfront acquisition value and the milestones payments, those deals can also receive royalty payments once the drug enters the market. These royalties provide long-term, recurring revenue without the burden of production or marketing costs. Our strategy aims to maximize financial returns, considering an upfront value, milestone payments and royalties, depending on the terms negotiated.